Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;8(7):945-57.
doi: 10.2217/epi-2016-0008. Epub 2016 Jul 19.

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation

Francine E Garrett-Bakelman  1 , Ari M Melnick  1
Affiliations
Review

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation

Francine E Garrett-Bakelman et al. Epigenomics. 2016 Jul.

Abstract

Aberrant epigenomic programming is a hallmark of acute myeloid leukemia. This is partially due to somatic mutations that perturb cytosine methylation, histone post-translational modifications and transcription factors. Remarkably, mutations in the IDH1 and IDH2 genes perturb the epigenome through all three of these mechanisms. Mutant IDH enzymes produce high levels of the oncometabolite (R)-2-hydroxyglutarate that competitively inhibits dioxygenase enzymes that modify methylcytosine to hydroxymethylcytosine and histone tail methylation. The development of IDH mutant specific inhibitors may now enable the therapeutic reprogramming of both layers of the epigenome spontaneously to revert the malignant phenotype of these leukemias and improve clinical outcome for acute myeloid leukemia patients with IDH mutations.

Keywords: AML; DNA methylation; IDH; epigenomics; histone tail methylation; hydroxymethylcytosine; leukemogenesis; mutation; targeted therapy; transcriptional regulation.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure The authors wish to thank the following sources of financial support: NCI R01CA198089 to AM Melnick, NCI K08CA169055 and funding from the American Society of Hematology (ASHAMFDP-20121) under the ASH-AMFDP partnership with The Robert Wood Johnson Foundation to FEG Bakelman. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

<b>Figure 1.</b>
Figure 1.. Overview of the IDH–TET2–WT1 leukemogenic axis.
Mitochondrial and cytosolic IDH enzymes as well as a subset of normal enzymatic steps from the TCA cycle are represented (blue box). In IDH mutant cells, IDH1 and IDH2 neomorphic enzymes (IDH1m and IDH2m) produce the oncometabolite 2-HG at high levels. 2-HG can inhibit the function of dioxygenase enzymes, including epigenetic modifiers (TET2, JMJC). TET2 and JMJC inhibition results in elevated levels of 5mC and histone lysine methylation respectively. These changes result in transcriptional dysregulation, which facilitates the acquisition of proliferative advantage and/or cell differentiation blockade. Malignant transformation can occur in IDHm cells in the presence of cooperative mutations. Mutations in WT1 (WT1m) that disrupt TET2 recruitment to WT1-target genes result in an alternative mechanism for transcriptional dysregulation and cell differentiation blockade. α-KG: α-ketoglutarate; 2-HG: (R)-enantiomer of 2-hydroxyglutarate; HKme: Methylated histones; hmC: Hydroxymethylcytosine; HMume: Unmethylated histones; IDHm: Mutant IDH enzymes; mC: Methyl-cytosine; TCA: Tricarboxylic acid.
<b>Figure 2.</b>
Figure 2.. IDH1 and IDH2 mutations in malignant disorders.
cBioPortal [22,23] frequency plots of amino acid substitutions resulting from mutations in IDH1 (A) and IDH2 (B) in malignant disorders (all cancer studies included). Green = missense mutations; red = inframe mutations (inframe deletion or insertion); black = truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site); purple = other mutations (all other mutation types).
See this image and copyright information in PMC

References

    1. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013;368(22):2059–2074. - PMC - PubMed

    2. •• Provides evidence to support that IDH1 and IDH2 genes are recurrently mutated in acute myeloid leukemia (AML).

    1. Meyer SC, Levine RL. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 2014;15(9):e382–e394. - PubMed
    1. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 2009;361(11):1058–1066. - PMC - PubMed

    2. • Reports first finding of IDH gene mutations in AML.

    1. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111(5):2505–2515. - PubMed
    1. Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) Blood (ASH Annual Meeting Abstracts) 2015;126(23):6.